Clinical Innovation: Week of June 19, 2026

As artificial intelligence enters healthcare, many companies are building specialized AI tools designed specifically for doctors. However, a new study tested these specialized medical tools against everyday, general-purpose AI models using real questions from physicians. Surprisingly, the general-purpose AI models performed much better. In fact, the specialized medical AI tools did no better than a standard Google search AI summary. This matters to regular people because it shows that 'specialized' medical technology is not always superior, and we must carefully test these tools before they are used to help guide patient care.

Researchers are highlighting a highly promising connection: people who get the live-attenuated shingles vaccine seem to have a lower risk of developing dementia. While this link is based on looking back at real-world patient data, experts from the U.S. National Institutes of Health and international panels agree the evidence is incredibly strong. To prove if the vaccine actually causes this protective effect, scientists are urgently calling for large-scale clinical trials. For now, the vaccine is only approved to prevent shingles, but this research could eventually open up a simple, existing way to help protect our brains as we age.

Scientists have developed a new artificial intelligence tool called PepALD to help design a special class of drugs known as macrocyclic peptides. These are ring-shaped molecules that are excellent at entering cells to treat complex diseases, but they are incredibly difficult to design by hand. Traditional computer models often treat the building blocks of these molecules like simple text, missing important chemical details. PepALD solves this by using advanced AI to understand the actual chemistry of the building blocks, predicting how they will fold and link together. In computer tests, PepALD designed high-quality drug candidates much faster than older methods, marking an exciting first step toward faster drug discovery.